急速進行性糸球体腎炎に伴う貧血のRecombinant Human Erythropoietin(rHu-EPO)による治療

概要

論文の詳細を見る
A 32-year-old Japanese male, a civil servant, was admitted to The Department of Medicine, Fukuoka Dental College Hospital because of rapidly progressive glomerulonephritis (RPGN) accompanied with nephrotic syndrome and mild renal insufficiency (BUN ; 33 to 59mg/dl, serum creatinine ; 1.73 to 2.77 mg/dl). To treat the progressive anemia accompanying the RPGN, recombinant human erythropoietin (rHu-EPO) was administered to the patient 21 times (total 36,000 unit) in the course of 11 weeks. Hematocrit increased from 22.7% to 33.5%, hemoglobin from 7.5g/dl to 11.6 g/dl and RBC from 253 × 10^4/mm^3 to 349 × 10^4/mm^3 respectively after the rHu-EPO therapy and a subjective improvement in fairly well-condition was noted. The platelet count increased slightly and serum potassim rather decreased slightly. The renal function was not significantly changed and BUN was decreased to about half the level before therapy. However, the serum creatinine concentration was hardly changed. There was no change in the liver function after rHu-EPO treatment. Blood pressure was slightly increased throughout the therapy, but both systolic and diastolic pressures remained within the normal range, and gradually returned to the pretherapeutic level after withdrawal of the rHu-EPO therapy.The only clinical side effect was flu-like syndrome. However, the complaint was mitigated and bearable by intravenous drip infustion of rHu-EPO. The patient's hematocrit still remains at 29.1% six months after withdrawal of the treatment. In conclusion, rHu-EPO was useful in the treatment of the anemia not only associated with chronic renal failure including hemodialyzed patients but also associated with rapidly progressive glomerulonephritis.
福岡歯科大学学会の論文
1991-03-31

急速進行性糸球体腎炎に伴う貧血のRecombinant Human Erythropoietin(rHu-EPO)による治療

スポンサーリンク

概要

著者

関連論文

スポンサーリンク